Treatment of chronic hepatitis C

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 133-137

  De Filippi, F ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic hepatitis C; HCV; Interferon; Peginterferon; Ribavirin; Therapy

Indexed keywords

ALPHA2B INTERFERON; AMINOTRANSFERASE; INTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ANEMIA; ANXIETY; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CANCER PREVENTION; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DRUG RESPONSE; EMOTIONAL DISORDER; ERADICATION THERAPY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENDER; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IRRITABILITY; LIFESPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; ORGAN TRANSPLANTATION; PANIC; PREDICTION; RELAPSE; RISK FACTOR; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT INDICATION; VIREMIA; VIRUS LOAD; WEIGHT REDUCTION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0141839658     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wong JB, McQuillan GM, McHutchison, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral heopatitis. N Engl J Med 1997; 226: 347-56.
3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
4. McHutchinson JG, Gordon SC, Shiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
5. EASL International Consensus Conference on Hepatitis C. Paris 26-28, February 1999: Consensus statement. J Hepatol 1999; 30: 956-61.
6. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
7. Lindsay KL, Trepo C, Heintges T, et al. A randomised, double-blindtrial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
8. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic heopatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Alberti A, Bonino F, Colombo M, Craxi A, Rizzetto M. Trattamento delle infezioni da HCV: Linee guida della Associazione Italiana per lo Studio del Fegato; 2003, (In press).
11. Davis G. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 (Suppl): S145-51.
12. Davis GL, Esteban Mur R, Rustgi V, et al. Recomnibant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
13. Jacobsen I. Pegylated interferonalfa-2b plus ribavirin in Patients with chronic hepatitis C: a trial in prior non-responders to interferon monotherapy or combination therapy and in combination therapy nonresponders. Gastroenterology 2002; 122: A626.
14. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
15. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomised, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.
16. Zdilar D, Franco-Bronson K, Buchler R, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-11.
17. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107-16.